EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Thoracic Society of Australia and New Zealand ( TSANZ ) position statement on chronic suppurative lung disease and bronchiectasis in children , adolescents and adults in Australia and New Zealand

Anne B Chang iD, Scott C Bell iD, Catherine A Byrnes, Paul Dawkins, Anne E Holland iD, Emma Kennedy, Paul T King iD, Pamela Laird iD, Sarah Mooney, Lucy Morgan, Marianne Parsons, Betty Poot und 3 weitere

Respirology · 2023-04 · 28 (4) · 339-349

DOI: 10.1111/resp.14479 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Respirology, online erschienen am 02.03.2023. Verfasst von Anne B Chang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Australian Centre for Health Services Innovation, Queensland University of Technology, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Bronchiectasis, Lung Diseases. Die Arbeit wurde bisher 80-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This position statement, updated from the 2015 guidelines for managing Australian and New Zealand children/adolescents and adults with chronic suppurative lung disease (CSLD) and bronchiectasis, resulted from systematic literature searches by a multi‐disciplinary team that included consumers. The main statements are: Diagnose CSLD and bronchiectasis early; this requires awareness of bronchiectasis symptoms and its co‐existence with other respiratory diseases (e.g., asthma, chronic obstructive pulmonary disease). Confirm bronchiectasis with a chest computed‐tomography scan, using age‐appropriate protocols and criteria in children. Undertake a baseline panel of investigations. Assess baseline severity, and health impact, and develop individualized management plans that include a multi‐disciplinary approach and coordinated care between healthcare providers. Employ intensive treatment to improve symptom control, reduce exacerbation frequency, preserve lung function, optimize quality‐of‐life and enhance survival. In children, treatment also aims to optimize lung growth and, when possible, reverse bronchiectasis. Individualize airway clearance techniques (ACTs) taught by respiratory physiotherapists, encourage regular exercise, optimize nutrition, avoid air pollutants and administer vaccines following national schedules. Treat exacerbations with 14‐day antibiotic courses based upon lower airway culture results, local antibiotic susceptibility patterns, clinical severity and patient tolerance. Patients with severe exacerbations and/or not responding to outpatient therapy are hospitalized for further treatments, including intravenous antibiotics and intensive ACTs. Eradicate Pseudomonas aeruginosa when newly detected in lower airway cultures. Individualize therapy for long‐term antibiotics, inhaled corticosteroids, bronchodilators and mucoactive agents. Ensure ongoing care with 6‐monthly monitoring for complications and co‐morbidities. Undertake optimal care of under‐served peoples, and despite its challenges, delivering best‐practice treatment remains the overriding aim.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BronchiectasisLung DiseasesChildHumansAdultAdolescentNew ZealandAustraliaAnti-Bacterial Agents

Stichwörter der Autor:innen

adolescentsadultsbronchiectasischildrenevidence base practicesystematic review

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Australian Centre for Health Services Innovation, Queensland University of Technology, Brisbane, Queensland, Australia.
  • Department of Respiratory & Sleep Medicine, Queensland Children's Hospital, Brisbane, Queensland, Australia.
  • NHMRC Centre for Research Excellence in Paediatric Bronchiectasis (AusBREATHE), Child Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
  • Thoracic Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.
  • Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
  • Translational Research Institute, Brisbane, Queensland, Australia.

ORCID-Profile: Anne B Chang, Scott C Bell, Anne E Holland, Paul T King, Pamela Laird

Förderung

  • National Health and Medical Research Council

Zitieren

APA

Chang, A. B., Bell, S. C., Byrnes, C. A., Dawkins, P., Holland, A. E., Kennedy, E., King, P. T., Laird, P., Mooney, S., Morgan, L., Parsons, M., Poot, B., Toombs, M., Torzillo, P. J., & Grimwood, K. (2023). Thoracic Society of Australia and New Zealand ( TSANZ ) position statement on chronic suppurative lung disease and bronchiectasis in children , adolescents and adults in Australia and New Zealand. Respirology, 28(4), 339-349. https://doi.org/10.1111/resp.14479

Vancouver

Chang AB, Bell SC, Byrnes CA, Dawkins P, Holland AE, Kennedy E, et al. Thoracic Society of Australia and New Zealand ( TSANZ ) position statement on chronic suppurative lung disease and bronchiectasis in children , adolescents and adults in Australia and New Zealand. Respirology. 2023;28(4):339-349. doi:10.1111/resp.14479

BibTeX
@article{Chang2023,
  author = {Chang, Anne B and Bell, Scott C and Byrnes, Catherine A and Dawkins, Paul and Holland, Anne E and Kennedy, Emma and King, Paul T and Laird, Pamela and Mooney, Sarah and Morgan, Lucy and Parsons, Marianne and Poot, Betty and Toombs, Maree and Torzillo, Paul J and Grimwood, Keith},
  title = {Thoracic Society of Australia and New Zealand ( TSANZ ) position statement on chronic suppurative lung disease and bronchiectasis in children , adolescents and adults in Australia and New Zealand},
  journal = {Respirology},
  year = {2023},
  volume = {28},
  number = {4},
  pages = {339--349},
  doi = {10.1111/resp.14479}
}
Kostenlos starten →